Abstract
Three platinum (II) complexes (6-8) with phthalate as the leaving group were synthesized and characterized by FTIR, 1H NMR, 13C NMR, mass spectrometry and elemental analysis. In-vitro cytotoxicity of all three complexes was evaluated using COLO 205 (human colon cancer cell line) against the parent drug “oxaliplatin”. The compound 4-amino-(transcyclohexane- 1,2-diamine) platinum(II) (8) showed potent cytotoxicity with IC50 = 0.12 µM as compared to oxaliplatin (IC50 = 0.19 µM) and its aqueous solubility was found to be 16 mg/mL which is higher than oxaliplatin (8 mg/mL). The acute toxicity showed that the platinum complex (8) was less toxic than oxaliplatin. Molecular oxaliplatin-DNA complex structure indicates that the diaminocyclohexane (DACH) and Pt (II) showed interactions with N7 and O6 of GG base pairs of DNA helix. In this present study, it is interesting to note that all three platinum based anticancer agents with phthalate as the leaving group exhibited great cytotoxicity, less toxicity, good lipophilicity as well as better aqueous solubility.
Keywords: Cytotoxicity, Lipophilicity, Oxaliplatin, Platinum complexes, trans-(±)-1, 2-Diaminocyclohexane.
Letters in Drug Design & Discovery
Title:Design, Synthesis and In-Vitro Cytotoxicity of Novel Platinum (II) Complexes with Phthalate as the Leaving Group
Volume: 10 Issue: 9
Author(s): Rajiv Sharma, Ravindra K. Rawal, Manav Malhotra, Tripti Gaba, A. K. Sharma and T. R. Bhardwaj
Affiliation:
Keywords: Cytotoxicity, Lipophilicity, Oxaliplatin, Platinum complexes, trans-(±)-1, 2-Diaminocyclohexane.
Abstract: Three platinum (II) complexes (6-8) with phthalate as the leaving group were synthesized and characterized by FTIR, 1H NMR, 13C NMR, mass spectrometry and elemental analysis. In-vitro cytotoxicity of all three complexes was evaluated using COLO 205 (human colon cancer cell line) against the parent drug “oxaliplatin”. The compound 4-amino-(transcyclohexane- 1,2-diamine) platinum(II) (8) showed potent cytotoxicity with IC50 = 0.12 µM as compared to oxaliplatin (IC50 = 0.19 µM) and its aqueous solubility was found to be 16 mg/mL which is higher than oxaliplatin (8 mg/mL). The acute toxicity showed that the platinum complex (8) was less toxic than oxaliplatin. Molecular oxaliplatin-DNA complex structure indicates that the diaminocyclohexane (DACH) and Pt (II) showed interactions with N7 and O6 of GG base pairs of DNA helix. In this present study, it is interesting to note that all three platinum based anticancer agents with phthalate as the leaving group exhibited great cytotoxicity, less toxicity, good lipophilicity as well as better aqueous solubility.
Export Options
About this article
Cite this article as:
Sharma Rajiv, Rawal K. Ravindra, Malhotra Manav, Gaba Tripti, Sharma K. A. and Bhardwaj R. T., Design, Synthesis and In-Vitro Cytotoxicity of Novel Platinum (II) Complexes with Phthalate as the Leaving Group, Letters in Drug Design & Discovery 2013; 10 (9) . https://dx.doi.org/10.2174/15701808113109990018
DOI https://dx.doi.org/10.2174/15701808113109990018 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Extracellular Matrix Regulates Cancer Progression and Therapy Response: Implications for Prognosis and Treatment
Current Pharmaceutical Design Pin1: A New Genetic Link between Alzheimer’s Disease, Cancer and Aging
Current Aging Science Modulation of the Type I Interferon Response Defines the Sensitivity of Human Melanoma Cells to Oncolytic Measles Virus
Current Gene Therapy Manipulating the Ability of Substituted Titanocene Derivatives to Induce Apoptosis in Castrate-Resistant Prostate Cancer Cells
Letters in Drug Design & Discovery Hypoxic Regulation of Metastasis via Hypoxia-Inducible Factors
Current Molecular Medicine Oncogenic Role of SET/I2PP2A for Gynecologic Cancers
Current Drug Targets A Comprehensive Review on the Medicinal Importance; Biological and Therapeutic Efficacy of <i>Lagenaria siceraria</i> (Mol.) (Bottle Gourd) Standley Fruit
Current Topics in Medicinal Chemistry Design, Synthesis and Biological Evaluation of Salicylamide Analogues as Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Letters in Drug Design & Discovery Hypericin Lights Up the Way for the Potential Treatment of Nasopharyngeal Cancer by Photodynamic Therapy
Current Clinical Pharmacology Chemical Structure Characteristics and Bioactivity of Small Molecule FAK Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Editorial (Thematic Issue: Current Research and Clinical Application in Head and Neck Radiotherapy)
Current Cancer Therapy Reviews MicroRNA-34 Family, Mechanisms of Action in Cancer: A Review
Current Cancer Drug Targets International Publication Trends in Proteasome Inhibitors: From Tools for Cell Biologists to Anticancer Agents
Letters in Drug Design & Discovery Folate Conjugated Solid Lipid Nanoparticles of Carboplatin for Targeting Cancer Cells
Drug Delivery Letters Recent Advances in Drug Design of Epidermal Growth Factor Receptor Inhibitors
Current Medicinal Chemistry Biology of PPARγ in Cancer: A Critical Review on Existing Lacunae
Current Molecular Medicine Sulfotransferase 1A1 as a Biomarker for Susceptibility to Carcinogenesis: From Molecular Genetics to the Role of Dietary Flavonoids
Current Drug Metabolism Role of Rap2 and its Downstream Effectors in Tumorigenesis
Anti-Cancer Agents in Medicinal Chemistry Drug-Eluting Stents: Present and Future
Cardiovascular & Hematological Agents in Medicinal Chemistry Cancer Vaccines for Hormone/Growth Factor Immune Deprivation:A Feasible Approach for Cancer Treatment
Current Cancer Drug Targets